GSK Exercises Its Option to License Ionis’ Antisense Therapy for Chronic Hepatitis B Virus Infection

 GSK Exercises Its Option to License Ionis’ Antisense Therapy for Chronic Hepatitis B Virus Infection

Shots:

  • Ionis to receive ~$262M milestones including $25M license fee with royalties on sales of products. GSK to exercise its option to license program following positive P-II results and will be responsible for all development, regulatory, commercialization activities and its costs 
  • In Mar’2010, GSK and Ionis collaborated on RNA therapies for rare and infectious diseases and granted GSK option to license and commercialize therapies at the clinical proof-of-concept
  • Ionis’ antisense technology targets the process of producing a protein before it even begins and has developed a first treatment for SMA in adults & children and world’s first RNA-targeted therapies for polyneuropathy in adults with hereditary transthyretin amyloidosis

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post